

Drug Monograph

Drug/Drug **Dexmedetomidine Hydrochloride concentrated solution**
 Class: **for injection / Sedatives**
 Prepared for: MO HealthNet
 Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

| | |
|-------------------------------|--|
| Purpose: | The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use. |
| Dosage Forms: | Dexmedetomidine hydrochloride is available in 100 mcg/ml strength. It is now available in a 4 ml vial that contains 400 mcg dexmedetomidine and in a 10 ml vial that contains 1,000 mcg dexmedetomidine respectively. |
| Manufacturer: | WG Critical Care, LLC., Paramus, NJ 07652 |
| Indications: | Dexmedetomidine hydrochloride is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. It is also indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures. |
| Costs: | \$78.92 per 4 ml vial and \$194.90 per 10 ml vial of dexmedetomidine hydrochloride. Wholesale Acquisition Cost |
| Summary of Findings: | MO HealthNet Division recommends Open Access status for this product. |
| Status Recommendation: | <input type="checkbox"/> Prior Authorization (PA) Required <input checked="" type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input type="checkbox"/> PDL |
| Type of PA Criteria: | <input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Under Solicitation <input type="checkbox"/> Appropriate Indications <input checked="" type="checkbox"/> No PA Required |

Prepared By: Luke Boehmer Pharm.D.
 Date: February 22, 2017